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Abstract 
Studies describing tumor as a hierarchically-organized cell population have changed 
the classical oncogenesis view and proposes new therapeutic strategies. Cancer 
stem cells (CSC) are thought to sustain tumor initiation/maintenance, therapy 
resistance, and systemic metastases. Targeting this tumor cell population is crucial to 
achieve a true cure. A large research effort is now aiming atdeveloping drugs 
targeting CSCs based either on a priori understanding of key pathways regulating 
CSC biology or high-throughput screening to identify novel targets and compounds.  
Background 
In recent years, tumor-initiating cells, so-called cancer stem cells (CSC), have been 
characterized in multiple cancers including breast cancer [1]. This component of 
cancer cells retains key stem cell properties, including self-renewal, which initiates 
and drives tumorigenesis, and differentiation albeit aberrant, which contributes to 
cellular heterogeneity. Moreover, CSCs are thought to be the seed for distant 
metastasis responsible for poor clinical outcome [2,3]. The discovery of CSCs 
provides an explanation as to why cancer may be so difficult to cure, and suggests 
new therapeutic strategies. Several studies demonstrate that breast CSCs are 
resistant to conventional therapeutic strategies such as radiotherapy or 
chemotherapy [2]. Thus, neoadjuvant chemotherapy leads to an increase in breast 
CD24-/CD44+ or ALDHhigh CSCs and tumorsphere-initiating-cells [4,5]. If these cells 
are the tumor root they are the cells to be killed.  
Two approaches have been developed to design the best therapeutic strategies 
targeting CSCs. The first approach is based on targeting key pathways regulating 
CSC survival, differentiation and self-renewal. Several master pathways (Hedgehog, 
NOTCH, and AKT/WNT/βcatenin signaling) commonly involved in self-renewal of 
embryonic and adult stem cells are known to be deregulated in CSCs and induce an 
expansion of this population [6]. A number of agents targeting these pathways are 
currently tested preclinically and some have entered clinical trials. Meanwhile, studies 
of CSC-enriched populations using Omics technologies are rapidly defining additional 
regulatory pathways and networks regulating CSC biology. We have recently 
established a gene expression signature that allowed the identification of CXCR1/IL8 
signaling as a key regulator pathway of breast CSC biology [7]. Utilizing a small 
molecule inhibitor of CXCR1, repertaxin, we were able to specifically target the CSC 
population in human breast cancer xenografts, retarding tumor growth and reducing 
metastasis [8].  
 
The article 
To identify novel drugs that target specifically CSCs researchers from Ciliberto’s 
group have privileged the second approach based on unbiased high-throughput 
screening (HTS) of small molecules libraries on CSC-enriched populations [9]. 
Because tumor cell population could contain very few CSCs, HTS needs be re-
designed to specifically measure gene inhibition or drug effect on the CSC 
population. In the MCF7 breast cancer cell line the authors described a cell 
population staining pale toluidine blue (Light Cells-LCs) enriched in CSCs. LCs had 
an increase in tumorsphere forming efficiency and were enriched for ALDHbright cells, 
described to exclusively contain the CSC population [7]. When transplanted in 
immunodeficient mice, LCs cells were highly tumorigenic compared to bulk MCF7 
cells. Utilizing this experimental system; Cioce et al. have done a drug screen assay. 
A total of 26 compounds were screened for their ability to kill specifically the LCs at a 
greater rate than the bulk MCF7 cells. The screen identified four such compounds, 
which all turned up to interfere with NFκB signaling [9].  
 
The viewpoint 
This unbiased drug screen strategy on CSC-enriched population was initially 
developed by the laboratories of R. Weinberg and E. Lander. The model used was 
experimentally-transformed HMLER breast cancer cells modified by shRNA-mediated 
inhibition of the human E-cadherin gene. Inhibition of E-cadherin expression induced 
an epithelial-mesenchymal transition (EMT) resulting in an increase in 
CD44high/CD24low cancer cells. A total of 32 compounds in a library of 16,000 
chemicals had selective toxicity for these artificially-enriched breast CSCs. Among 
these, salinomycin was the most potent. The use of this potassium ionophore 
inhibitor as a potential cancer drug is novel and was validated in vivo using breast 
cancer cell line xenografts, with a decrease in tumor growth and metastasis formation 
[10]. A similar approach has been developed for human brain tumors with the 
establishment of several glioma neural stem cell lines stably enriched in CSCs. 
Utilizing cell imaging-based chemical screen (450 FDA-approved drugs) P. Dirks’ 
group identified both differential sensitivities of CSCs and a common susceptibility to 
perturbation of serotonin signaling [11]. This suggests that CSCs might be highly 
susceptible to metabolic changes and open new therapeutic possibilities. 
Other than test selective drug toxicity on an enriched-CSC population compared to 
bulk cancer cells, HTS can be designed to directly measure drug effect on CSC 
function. Exploiting the relationship between neural stem cells self-renewal and 
neurosphere proliferation, a screen of more than 1,200 compounds identified several 
neuromodulators as key regulators of stem cell biology [12]. A similar approach may 
be envisaged with tumorsphere from breast cancer cell lines.  
Instead of chemicals, RNA interference libraries can be screened to identify factors 
that control CSC tumorigenicity and to stimulate the development of novel anti-CSC 
therapies. A recent kinome-wide RNA interference screen identified factors that 
control the balance between maintenance and differentiation of glioblastoma CSCs. 
For example, silencing of TRRAP was described to increase differentiation of 
glioblastoma CSCs in vitro and also suppressed tumor formation in vivo [13].  
In conclusion, HTS assays of CSCs provide opportunities to identify multiple 
compounds that could represent new revolutionary therapies. Because these novel 
compounds will be selected in vitro, it will be crucial to extensively validate in vivo the 
selective toxicity of these drugs toward CSCs , utilizing primary tumor xenografts as a 
preclinical step. Moreover, serial transplantation of the residual cells isolated from 
treated-tumors will be needed to prove the complete eradication of the tumor-
initiating cell population. If the fishing season is officially open, the question remains 
how to choose the best bait. Hence, developing therapeutic strategies to target CSCs 
will need a thorough and rigorous effort as many challenges remain to overcome 
such as the evaluation of drug efficiency in the patients [14].  
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